VEEV Veeva Systems Inc.

Veeva Systems is making that transformation happen. The Pleasanton, Calif.–based company develops software for biotechnology and pharmaceutical customers to manage everything from research and development and regulatory submissions to day-to-day commercial operations. Its software was originally built atop Salesforce but has since expanded to stand-alone applications.

Veeva (VEEV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Based on the average brokerage recommendation (ABR), Veeva (VEEV) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Veeva Systems has underperformed the Dow over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Veeva Systems (VEEV) closed the most recent trading day at $280.68, moving +2.12% from the previous trading session.

Stock Market Today: The Dow Jones index rises Friday on U.S.-Iran peace hopes. Micron stock and Sandisk rally Friday.

VEEV's AI-powered Study Builder Agent automates clinical study setup, cutting manual work while strengthening its connected Clinical Data ecosystem.

Veeva (VEEV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

In recent days, Veeva Systems has rolled out new AI-powered tools such as Veeva Study Builder Agent and Veeva Falcon Router, while announcing major customer wins including Oxford Biomedica adopting Veeva Quality Cloud and Amgen planning a global deployment of Veeva Vault CRM. Together, these developments highlight Veeva’s push to embed agentic AI across clinical, safety, quality, and commercial workflows, reinforcing its role as an end-to-end software partner for life sciences...

Veeva Systems launches new AI study design agent Veeva Systems (VEEV) has unveiled Veeva Study Builder Agent, an AI tool that configures its EDC and Data Quality System directly from a clinical study protocol, aiming to streamline and standardize trial setup. Recent AI product launches and new client wins have arrived alongside a sharp 71.27% 90 day share price return and an 8.97% 30 day share price return for Veeva Systems, while the 1 year total shareholder return is slightly down 2.59%,...

Doximity (DOCS), which calls itself the leading digital platform for U.S. medical professionals, has seen its stock fall steeply over the past year. Even after a rise over the past three months, the shares sit about 65% below their 52-week high. Management continued its repurchase program, allocating approximately $401 million over the latest twelve months. The test is whether it can keep that up through what it calls its AI investment year.

VEEV launches Falcon Router to automate biopharma case routing, deepening AI integration across regulated life sciences workflows.

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

VEEV expands its decade-long Amgen partnership with a global Vault CRM rollout, reinforcing enterprise adoption and commercial subscription growth.

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.

Trade Desk’s healthcare data push Trade Desk (TTD) is back in focus after expanding its integrations with healthcare data specialists Veeva Systems and IQVIA, giving pharma advertisers more granular campaign insights directly inside its advertising platform. Recent trading has been rough for Trade Desk, with the share price down 24.8% over the past 90 days and the year-to-date share price return declining 63.1%, while the 1-year total shareholder return is down 68.7%. This points to fading...

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Veeva (VEEV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

What a fantastic six months it’s been for Veeva Systems. Shares of the company have skyrocketed 43%, hitting $265. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Veeva Systems (NYSE:VEEV) is positioning artificial intelligence as an incremental growth opportunity beyond its previously stated goal of reaching $6 billion in revenue by 2030, according to executives speaking at a Wells Fargo healthcare technology event. Paul Shawah, Veeva’s EVP of Commercial St

Veeva Systems (NYSE:VEEV) CFO Brian Van Wagener said the company is expanding its artificial intelligence roadmap while continuing to see broad-based growth across its life sciences software portfolio. Speaking at Citi’s Tech Conference, Van Wagener described Veeva as a vertical software provider f

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

Michael Burry remains bullish on Veeva but trimmed his stake after shares jumped more than 15% on a fiscal second-quarter earnings beat and a raised 2027 outlook.

Veeva Systems (NYSE: VEEV) announced that Regeneron and Biogen have adopted its AI powered Vault CRM suite globally. The company also introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. Both moves expand Veeva Systems' AI focused offering across commercial and safety workflows in life sciences. These updates highlight how AI heavy software is becoming core infrastructure for healthcare and biopharma workflows. This connects directly to a wider set...

Veeva raises its fiscal 2027 outlook as Vault CRM adoption, R&D growth and Falcon AI momentum support expanding revenue and profitability.

VEEV's strong Q2 results, Vault CRM migrations and AI expansion support growth, while market saturation remains a key concern.

One software rally still looks attractive, another far less so

Michael Burry Takes Profits in Veeva. But He Has a Stark Warning for Snowflake

This article first appeared on GuruFocus. Michael Burry (Trades, Portfolio) still likes Veeva Systems Inc. (VEEV, Financials) as a software play even after he just decreased his position in Big Short investor Michael Burry (Trades, Portfolio)'s portfolio.

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

The investor says sharp selloffs can create opportunities to accumulate more shares, while cautioning that conviction must be balanced against valuation and risk.

Thomas D. Schwenger exercised options and sold 10,000 shares under a pre-arranged trading plan, retaining 19,449 directly held shares.

The real bet is on what lies beyond this year's performance: a pipeline that could change everything.

During the August 31 episode of Mad Money, Jim Cramer examined the sharp rotation back into enterprise software following the forced unwinding of bearish hedge fund positions. Mentioning Veeva Systems Inc. (NYSE:VEEV) and Salesforce, Inc. (NYSE:CRM) as examples of sector leaders, he commented: Situational Awareness just despised enterprise software and Veeva Systems, number three, up […]

The biggest opportunity for the stock isn't some futuristic gadget, but a powerful dynamic hiding in plain sight in its latest results.

Burry followed a simple trade management rule.

Moderna stock led the index after melanoma vaccine data, while a hedge fund's forced unwind turbocharged a rebound in enterprise software

Revenue hit $928M with 18% growth as Vault CRM adoption accelerates.

Veeva Systems Inc. (NYSE:VEEV) delivered a fiscal second-quarter report that renewed interest in profitable software growth. Revenue rose 18% year over year to $928 million, while subscription revenue increased 16% to $766.8 million. GAAP operating income climbed 40% to $275 million, lifting the operating margin to 29.6% from 24.8%. That improvement was real, but the […]

The “Big Short” investor says he is redeploying capital from Veeva into “spring-loaded positions” while waiting for PayPal to fall further before adding.

Veeva Systems' recent beat-and-raise quarter has investors feeling bullish.

Shares of life sciences cloud software provider Veeva Systems (NYSE:VEEV) jumped 17% in the afternoon session after the company reported second-quarter financial results that exceeded Wall Street expectations for revenue and adjusted earnings.

What the latest earnings and guidance tell you about Veeva Systems Veeva Systems (VEEV) just reported quarterly results that came in ahead of analyst expectations and paired them with higher guidance, putting fresh attention on how its AI focused life sciences cloud products are performing. The company reported second quarter revenue of US$927.96 million compared with US$789.08 million a year earlier. Net income was US$273.43 million compared with US$200.31 million a year ago, with diluted...

Life sciences cloud software provider Veeva Systems (NYSE:VEEV) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 17.6% year on year to $928 million. Guidance for next quarter’s revenue was better than expected at $933.5 million at the midpoint, 1.5% above analysts’ estimates. Its non-GAAP profit of $2.35 per share was 5.8% above analysts’ consensus estimates.

Veeva Systems (VEEV) is executing successfully across customer relationship management, artificial i

The cloud specialist in the life sciences industry delivered remarkably solid results.

FEATURE Stocks rallied Thursday as a batch of stellar earnings reports, including one from Nvidia revived Wall Street’s appetite for tech stocks. Nvidia shares rose 7.7% after the chip maker’s second-quarter earnings topped analysts’ expectations.

VEEV's Q2 fiscal 2027 earnings and revenues top estimates, while strong Vault CRM momentum and a raised full-year outlook drive shares higher.

Veeva Systems stock surges and is having its best day ever after the software company’s quarterly earnings and guidance made Wall Street believers.